Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts rate Aardvark Therapeutics “Hold” overall: Five analysts recommend buying, four say hold, two recommend selling, and one gives a strong buy rating. The average 12-month price target is $15.33, versus a recent share price of $5.75.
• Aardvark reported a quarterly loss of $0.66 per share, beating the consensus estimate of a $0.87 loss; analysts expect a full-year loss of approximately $3.17 per share.
• Legal and clinical risks have increased: Shareholder lawsuits allege the company overstated ARD-101’s safety after the Phase 3 HERO trial was paused and the FDA placed a clinical hold on the program. These remain allegations, and investors seeking to lead the proposed class action must act by October 13, 2026.

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been assigned a consensus rating of "Hold" from the twelve analysts that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $15.3333.

Several analysts have commented on the stock. HC Wainwright reissued a "neutral" rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Wall Street Zen raised shares of Aardvark Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 2nd.

Aardvark Therapeutics Trading Up 3.2%

AARD opened at $5.75 on Wednesday. The firm has a market cap of $125.81 million, a price-to-earnings ratio of -1.79 and a beta of 3.74. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.94. The stock has a fifty day moving average price of $6.22 and a 200-day moving average price of $5.29.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.21. On average, equities research analysts forecast that Aardvark Therapeutics will post -3.17 EPS for the current year.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Negative Sentiment: The lawsuit, filed in the U.S. District Court for the Southern District of California under docket 26-cv-04643, targets Aardvark and certain officers and directors. The proposed class includes investors who bought shares in or traceable to the February 2025 IPO, as well as securities purchased between February 13, 2025, and May 14, 2026. Plaintiffs are pursuing claims under the Securities Act of 1933 and Securities Exchange Act of 1934. Pomerantz class action announcement
• Negative Sentiment: Investor notices allege that Aardvark overstated the safety profile of ARD-101. The allegations follow the pause of the Phase 3 HERO trial and an FDA clinical hold, events that reportedly contributed to Wall Street price-target reductions from as high as $29 to approximately $7. These are allegations, and no wrongdoing has been established. AARD shareholder alert
• Neutral Sentiment: The numerous announcements from Rosen, Hagens Berman, Bernstein Liebhard, Faruqi & Faruqi, Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, and other firms largely repeat the same information and deadline rather than introduce a new company operating update. Investors seeking to lead the case must act by October 13, 2026. Hagens Berman Aardvark deadline notice

Insider Activity

In other news, insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the sale, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. This represents a 63.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 17.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new position in Aardvark Therapeutics during the 2nd quarter valued at about $138,000. J. Goldman & Co LP purchased a new stake in shares of Aardvark Therapeutics during the second quarter worth about $233,000. Ieq Capital LLC purchased a new stake in shares of Aardvark Therapeutics during the second quarter worth about $221,000. BlackRock Inc. purchased a new stake in shares of Aardvark Therapeutics during the second quarter worth about $1,077,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Aardvark Therapeutics during the first quarter valued at about $267,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company's approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.

Aardvark's lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.